IRB Policies on Clinical Trials during COVID-19

Here are links to examples of IRB policies on how COVID-19 is affecting clinical trials at research institutions. 

This list accompanies our post on the Impact of COVID-19 on Clinical Trials. The list is provided for your convenience and is not based on where our clients are sponsoring clinical studies (although we have negotiated with many of these sites).

UCLA Clinical and Translational Science Institute:

COVID-19 – Updates March 2020

MedStar Health Research Institute:

Research Activities During COVID-19

NYU Update:

Research Operations During COVID19

Duke University Research:

Coronavirus (COVID-19) Research-Related Updates

Johns Hopkins Institutional Review Board:

COVID-19 FAQs

Columbia University Research:

COVID-19 (Novel Coronavirus): FAQs Relating to Research

Northwestern University IRB:

IRB Office COVID-19 Memo to Research Community

Emory University Office of Research Administration:

Research Guidance During COVID-19

University of Michigan:

COVID-19 Research Operations

University of Michigan:

COVID-19 Guidance for the Research Community

Baylor University:

COVID-19 Research Update

Boston University Medical Campus and Boston Medical Center IRB:

FAQs: Impact of COVID-19 on Human Subjects Research

DF/HCC Dana Farber/Harvard Cancer Center:

Update on Potential Protocol Deviations and Violations Related to COVID-19 Precautions

University of Texas at Austin at Austin:

COVID-19 Considerations for Human Subject Research

UC Davis Office of Research:

Research Continuity & Planning for COVID-19

University of Washington Research:

COVID-19 and Human Subjects Research

USC University of Southern California Office for the Protection of Research Subjects:

COVID-19 FDA Guidance

UT Southwestern Medical Center:

Impact of COVID-19 on Researchers

Penn State:

COVID-19: Human Subjects

University of Pittsburgh HRPO:

COVID-19 (Coronavirus)

Boston Children’s Hospital/Harvard Medical School Teaching Hospital:

IRB New COVID-19

University of North Carolina at Chapel Hill:

Office of the Vice Chancellor for Research Responds to COVID-19 (Updated 3/24/2020)

Ohio State University Office of Research Practices:

Interim Ohio State Guidance and FAQs on Human Subjects-Related Research Visits During COVID-19 Outbreak

Pennington Biomedical Research Center:

Memo:  COVID-19 Study Related Issues: This memo applies only to COVID-19 related issues resulting in a deviation from the protocol.

If you have any questions or would like more information about these developing issues, please contact the following:

KATHERINE LEIBOWITZ
1-610-896-5788
Katherine.Leibowitz@LeibowitzLawTeam.com